Company Filing History:
3 out of 11 
1 out of 103 
1 out of 10 Years Active: 2022-2025
Title: Innovations by Francisca Wollerton Van Horck
Introduction
Francisca Wollerton Van Horck is an accomplished inventor based in Cambridge, GB, recognized for her significant contributions to the field of biomedicine. With a total of five patents to her name, her work primarily focuses on innovative therapeutic solutions aimed at combating cancer through targeted binding members.
Latest Patents
Among her latest patents is the "LAG-3 Binding Members," which explores specific binding members that target the lymphocyte-activation gene 3 (LAG-3). This invention demonstrates a remarkable application in cancer therapy, utilizing a binding site located within the CH3 domain's structural loops. Another pivotal patent is the "Bispecific Antibody for ICOS and PD-L1," which features a multispecific antibody in a mAb2 format encompassing an ICOS-binding Fab region and a PD-L1-binding Fcab region. This innovative antibody is designed for use in immuno-oncology, specifically for treating solid tumors in combination therapies that involve other immune checkpoint inhibitors like PD-1 and CTLA-4.
Career Highlights
Throughout her career, Francisca has made substantial strides while working with notable companies such as F-star Therapeutics and Kymab Limited. Her experience in these leading organizations has fine-tuned her skills in developing revolutionary therapeutic products that address urgent medical challenges.
Collaborations
Collaboration plays a vital role in innovation, and Francisca has had the opportunity to work alongside esteemed colleagues, including Mihriban Tuna and Katy Louise Everett. Their teamwork has contributed to advancing research and enhancing the efficacy of the inventions within the realm of immunology.
Conclusion
Francisca Wollerton Van Horck's inventive spirit and dedication to her field have enabled her to emerge as a pioneering force in biomedicine. Her latest patents underscore her commitment to exploring innovative approaches to cancer treatment, and her collaborations reflect the collective effort required to drive scientific advancements. With continued exploration and determination, she is poised to contribute further to the world of innovations in health care.